DrugPatentWatch Database Preview
J And J Company Profile
Email this page to a colleague
See Plans and PricingWhat is the competitive landscape for J AND J, and when can generic versions of J AND J drugs launch?
J AND J has thirty-two approved drugs.
There are six US patents protecting J AND J drugs.
There are sixty-nine patent family members on J AND J drugs in forty-one countries and twenty-eight supplementary protection certificates in twelve countries.
Summary for J And J
| International Patents: | 69 |
| US Patents: | 6 |
| Tradenames: | 25 |
| Ingredients: | 12 |
| NDAs: | 32 |
Drugs and US Patents for J And J
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J And J Consumer Inc | IMODIUM A-D | loperamide hydrochloride | SUSPENSION;ORAL | 019487-002 | Jul 8, 2004 | OTC | Yes | Yes | Start Trial | Start Trial | |||||
| J And J Consumer Inc | PEPCID AC | famotidine | TABLET;ORAL | 020325-002 | Sep 23, 2003 | OTC | Yes | Yes | Start Trial | Start Trial | |||||
| J And J | GRIFULVIN V | griseofulvin, microcrystalline | TABLET;ORAL | 060618-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for J And J
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| J And J Consumer Inc | IMODIUM MULTI-SYMPTOM RELIEF | loperamide hydrochloride; simethicone | TABLET;ORAL | 021140-001 | Nov 30, 2000 | 5,248,505 | Start Trial |
| J And J Consumer Inc | PEPCID AC | famotidine | TABLET;ORAL | 020325-001 | Apr 28, 1995 | 5,667,794*PED | Start Trial |
| J And J Consumer Inc | CHILDREN'S MOTRIN | ibuprofen | SUSPENSION;ORAL | 020516-001 | Jun 16, 1995 | 5,374,659*PED | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for J AND J drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Chewable Tablets | 5 mg and 10 mg | ➤ Subscribe | 2005-03-25 |
| ➤ Subscribe | Syrup | 5 mg/5 mL | ➤ Subscribe | 2007-03-19 |
| ➤ Subscribe | Chewable Tablets | 800 mg/ 10 mg/ 165 mg (OTC) | ➤ Subscribe | 2004-11-01 |
International Patents for J And J Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Poland | 206069 | Start Trial |
| Israel | 159287 | Start Trial |
| Saudi Arabia | 534 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for J And J Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0720599 | 122014000088 | Germany | Start Trial | PRODUCT NAME: EZETIMIB ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON IN KOMBINATION MIT ATORVASTATIN ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON, INSBESONDERE ATORVASTATIN ALS ATORVASTATINCALCIUMTRIHYDRAT; NAT. REGISTRATION NO/DATE: 90223.00.00 20141113; FIRST REGISTRATION: FRANKREICH CIS: 6 928 917 6 20140912 |
| 0933372 | PA2008006 | Lithuania | Start Trial | PRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712 |
| 1110543 | 08C0004 | France | Start Trial | PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
